<DOC>
	<DOCNO>NCT01202695</DOCNO>
	<brief_summary>Primary : â€¢ To compare safety profile single intravenous administration AVP-21D9 compare Placebo Secondary : - To evaluate pharmacokinetics ( PK ) single intravenous administration AVP-21D9 - To evaluate immunogenicity AVP-21D9</brief_summary>
	<brief_title>Safety Pharmacokinetics Study Human Monoclonal Antibody ( AVP-21D9 )</brief_title>
	<detailed_description>This sequential , dose-escalating healthy volunteer study safety pharmacokinetics intravenously-infused AVP-21D9 .</detailed_description>
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Healthy volunteer , 18 45 year age Normal laboratory ( blood test ) result Key Prior immunization anthrax vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>